- In April 2024, Pfizer Inc. announced the launch of a nationwide awareness campaign aimed at improving statin adherence among high-risk cardiovascular patients. This initiative, titled Heart Strong, includes educational materials, digital tools, and community outreach events to address misconceptions about statin side effects and encourage regular cholesterol monitoring. By promoting proactive heart health management, Pfizer is reinforcing its leadership in the U.S. statin space and supporting population-level cardiovascular risk reduction
- In March 2024, Amgen Inc. expanded its collaboration with primary care providers and telehealth platforms to enhance access to statin therapy and lipid management services. The initiative includes the integration of statin prescriptions into virtual care pathways, ensuring broader accessibility for patients in remote and underserved regions. This strategic move reflects Amgen’s ongoing efforts to support equitable cardiovascular care and strengthen its footprint in the digital health landscape
- In March 2024, Viatris Inc. announced the introduction of an enhanced patient support program for its generic atorvastatin, offering digital adherence tools, mobile app integration, and personalized pharmacist consultations. This development aims to improve long-term statin compliance among Medicare beneficiaries and low-income populations, underscoring Viatris’s commitment to affordability and therapeutic continuity in chronic disease management
- In February 2024, Merck & Co., Inc. launched a new fixed-dose combination therapy trial in the U.S., combining simvastatin with an investigational antihypertensive agent for patients with comorbid conditions. The clinical trial is part of Merck’s broader strategy to expand its cardiovascular portfolio through innovation in combination treatments, addressing the evolving needs of polypharmacy patients and driving therapeutic simplification
- In January 2024, AstraZeneca announced real-world evidence (RWE) results from a U.S.-based observational study confirming the long-term cardiovascular benefits of rosuvastatin in high-risk populations. The study, presented at the American College of Cardiology’s Annual Scientific Session, reinforces the clinical value of rosuvastatin and supports its continued use in guideline-directed therapy. This evidence-based validation further strengthens AstraZeneca’s positioning in the statin market
